drugset
drugset / Trial / NCT05214677

A Phase 1 Clinical Trial to Evaluate the Safety and Pharmacokinetic Characteristics of DW1809

NCT05214677 ↗

Phase 1 Completed 38 enrolled Daewon Pharmaceutical Co., Ltd.
RandomizedCrossoverOpen-labelTreatment

Summary

Randomized, Open-label, Oral, Single-dose, two-Sequence, four-Period, crossover study

Timeline

Start
2020-08-15
Primary completion
2020-09-07
Completion
2020-09-07

Drugs

EvaluationDrugModalityDoseRoute
Subject Pelubiprofen Small molecule 30 mg Oral

Indications

osteoarthritis respiratory tract infectious disorder rheumatoid arthritis